Description
Regenerative Medicine Market: Information by Type (Cell Therapy, Gene Therapy, Tissue Engineering, Small Molecule & Biologic), by Material (Synthetic, Genetically Engineered, Biologically Derived), by Application (Musculoskeletal Disorders, Wound Care, Oncology, Ocular Disorders, Diabetes), by End User (Hospitals, Specialty Centers, Academic & Research Institutes), and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa) – Forecast till 2027
Market Review
The regenerative medicine market is evaluated to register a substantial CAGR of 21.18% during the projected timeframe to surpass USD 152,501.51 million by 2027. Regenerative medicine is the part of medicine that creates techniques to regrow, fix or supplant harmed or unhealthy cells, organs, or tissues. Regenerative medicine incorporates the age and utilization of helpful undifferentiated cells, tissue designing, and the creation of dummy organs.
The worldwide regenerative medicine market is developing quickly and is anticipated to keep developing at a consistent rate during the review time frame. This is because of the developing commitment of existing players to make the item more viable. The inventory network investigation for the regenerative medicine market contains four significant parts, which start with the examination and item advancement followed by assembling of the items, conveyance, and deals, and finishes with post-deals administrations. Variables that impact the regenerative medicine market are expanding headway in medical services innovation, cutting edge innovation in the regenerative medicine market, expanding pervasiveness of constant infections, and expanding development in foundational microorganism innovation.
Segment Overview
The global regenerative medicine market has been divided based on type, material, application, and end-user. In terms of material type the global market has been classified into synthetic, genetically engineered, biologically derived, and others.
By Type, the global market has been dispersed into cell therapy, Gene Therapy, Tissue Engineering, and Small Molecule & Biologic. The application segment categorizes the global market as musculoskeletal disorders, wound care, oncology, ocular disorders, diabetes, and others.
In terms of end-user, the regenerative medicines market is divided into hospitals, specialty centers, academic & research institutes, and others.
Regional Analysis
The region-specific analysis of the global regenerative medicine market has been classified into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
The Americas is likely to drive the largest market of the global regenerative medicines market during the review period. the regional market is attributed to the favorable government policies, and establishment of institutions such as the American Academy of Regenerative Medicine (AARM) and the American Board of Regenerative Medicine (ABRM), rising monetary support by investors. Europe additionally represented a huge portion of the overall industry attributable to the accomplishment of the skillet European undertakings (like CHRODIS and CHRODIS PLUS), government drives, public and private examination funders, and community-oriented logical exploration projects in the field of regenerative medicine.
Asia-Pacific is assessed to be huge in regenerative medicine treatment because of changes in medical care foundation, cross-country logical exploration projects, and preparing of scientists and youthful resources at driving establishments in the field of tissue designing and undifferentiated organism-based examination.
Major Players
The major players of the global regenerative market include Zimmer Biomet Holdings Inc. (US), AbbVie Inc. (US), Cryolife, Inc. (US), Stryker (US), Medtronic Plc (Ireland), Baxter International Inc. (US), Organogenesis Inc. (US), Ocata Therapeutics Inc. (US), Integra Lifesciences Holdings Corporation (US), Vericel Corporation (US), and Reliance Life Sciences (India)
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
1.1.1 MARKET SYNOPSIS
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 LIST OF ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES AND GENETIC DISORDERS
4.2.2 GROWING ADOPTION OF STEM CELL TECHNOLOGY
4.2.3 RISING PRODUCT PIPELINE OF REGENERATIVE MEDICINE
4.3 RESTRAINT
4.3.1 ETHICAL CONCERNS FOR THE USE OF EMBRYONIC STEM CELLS
4.4 OPPORTUNITY
4.4.1 IMPLICIT GUIDELINES BY THE INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH (ISSCR) RELATED TO THE EXTENDED EMBRYO CULTURE
4.5 COVID-19 IMPACT ANALYSIS
4.5.1 IMPACT ON MARKET PLAYERS
4.5.2 BRANDED AND GENERIC DRUGS IMPACT ANALYSIS
4.5.3 R&D IMPACT ANALYSIS
4.5.4 FDA POLICIES
4.5.5 OPPORTUNITY ANALYSIS
4.6 PIPELINE ANALYSIS: GLOBAL REGENERATIVE MEDICINE MARKET
5 MARKET FACTOR ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
6 GLOBAL REGENERATIVE MEDICINE MARKET, BY TYPE
6.1 OVERVIEW
6.2 CELL THERAPY
6.3 GENE THERAPY
6.4 TISSUE ENGINEERING
6.5 SMALL MOLECULE & BIOLOGIC
7 GLOBAL REGENERATIVE MEDICINE MARKET, BY MATERIAL
7.1 OVERVIEW
7.2 SYNTHETIC
7.3 GENETICALLY ENGINEERED
7.4 BIOLOGICALLY DERIVED
7.5 OTHERS
8 GLOBAL REGENERATIVE MEDICINE MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 MUSCULOSKELETAL DISORDERS
8.3 WOUND CARE
8.4 ONCOLOGY
8.5 OCULAR DISORDERS
8.6 DIABETES
8.7 OTHERS
9 GLOBAL REGENERATIVE MEDICINE MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CENTERS
9.4 ACADEMIC & RESEARCH INSTITUTES
9.5 OTHERS
10 GLOBAL REGENERATIVE MEDICINE MARKET, BY REGION
10.1 OVERVIEW
10.2 AMERICAS
10.2.1 NORTH AMERICA
10.2.1.1 U.S
10.2.1.2 CANADA
10.2.2 LATIN AMERICA
10.3 EUROPE
10.3.1 WESTERN EUROPE
10.3.1.1 GERMANY
10.3.1.2 FRANCE
10.3.1.3 UK
10.3.1.4 ITALY
10.3.1.5 SPAIN
10.3.1.6 REST OF WESTERN EUROPE
10.3.2 EASTERN EUROPE
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.2 INDIA
10.4.3 JAPAN
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 REST OF ASIA PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 MIDDLE EAST
10.5.2 AFRICA
11 COMPETITIVE LANDSCAPE
11.1 COMPETITIVEOVERVIEW
11.2 COMPETITOR DASHBOARD
11.3 MAJOR PLAYERS IN THE GLOBAL REGENERATIVE MEDICINE MARKET
11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL REGENERATIVE MEDICINE MARKET
11.5 COMPETITIVE BENCHMARKING
11.6 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL REGENERATIVE MEDICINE MARKET
11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.7.1 NEW PRODUCT DEVELOPMENTS/LAUNCHES
11.7.2 COLLABORATIONS/ EXPANSIONS/PARTNERSHIPS/JOINT VENTURES
11.8 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO
11.8.1 SALES & OPERATING INCOME
11.8.2 R&D EXPENDITURE
12 COMPANY PROFILES
12.1 ZIMMER BIOMET HOLDINGS INC.
12.1.1 COMPANY OVERVIEWS
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 ABBVIE INC.
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 CRYOLIFE, INC.
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 STRYKER
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS/SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 MEDTRONIC PLC
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS/SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 BAXTER INTERNATIONAL INC.
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 ORGANOGENESIS INC.
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS/SERVICES OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 OCATA THERAPEUTICS INC.
12.8.1 COMPANY OVERVIEW
12.8.4 KEY DEVELOPMENTS
12.9 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 VERICEL CORPORATION
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.10.6 KEY STRATEGIES
12.11 RELIANCE LIFE SCIENCES
12.11.1 COMPANY OVERVIEW
12.11.2 FINANCIAL OVERVIEW
12.11.3 PRODUCTS/SERVICES OFFERED
12.11.4 KEY DEVELOPMENTS
12.11.5 SWOT ANALYSIS
12.11.6 KEY STRATEGIES
Reviews
There are no reviews yet.